Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

Inclusion Criteria: * Subject has type 1 or type 2 diabetes mellitus * Subject has documented diagnosis of gastroparesis by: * Delayed gastric emptying (gastric retention ≥60% at 2h and ≥10% at 4 h; based on scintigraphy -4h standardized radionuclide solid meal) * A minimum 3 month history of chronic upper abdominal discomfort (two or more: chronic postprandial fullness, bloating, epigastric discomfort, early satiety, belching after meal, postprandial nausea, vomiting) * Subject has normal upper endoscopy * If female, must be permanently sterilized or postmenopausa. Exclusion Criteria: * Patient has received any investigational drug within the preceding 30 days * Patient is taking unstable doses of medication that affects gastric motility * Patient has co-morbid condition * Patient has a positive laboratory test result for hepatitis B, hepatitis C, HIV, or controlled substances. * Patient has a history of a psychiatric disorder (including drug or alcohol addiction) requiring care by a psychiatrist or psychologist within the preceding 12 months. * Patient has a recent,adult history of clinically significanthypersensitivity reaction(s) to any drug. * Patient has known history of alcoholism